Project Grant R21AG087396

Award Date 4/15/24
Completion Date 3/31/26
Dollars Obligated $392K
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $308,000.00 to the Regents of the University of Minnesota to investigate the impact of amyloid-beta (Aβ42) on mitochondrial liquid-liquid phase separation in Alzheimer's disease. The overarching goal is to identify the mechanisms by which Aβ42 interferes with mitochondrial gene expression and causes mitochondrial dysfunction. The project will pursue two specific aims: (1) investigating the...
This $466,125 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) supports research by President and Fellows of Harvard College (Harvard Medical School) to investigate the effects of Alzheimer's disease on subcellular transcriptome dynamics and mitochondrial-nuclear coordination in neuronal cell compartments. The project aims to analyze RNA flow kinetics, transcriptome composition, and translational regulation in the soma and neuronal projections of cells...
This Project Grant award of $705,775 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a comprehensive study of mitochondrial diversity in the aging brain and immune system. The primary objectives are to: Generate high-resolution mitochondrial gene expression profiles ("mitotypes") for over 1.4 million brain cells and 0.9 million immune cells from older adults to identify mitochondrial recalibrations associated with age, sex, cognitive reserve, and...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the NIH's Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), provides $459,250 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop an isogenic human neural stem cell model and evaluate mitochondrial transfer as a potential therapeutic intervention for Spinal Bulbar Muscular Atrophy (SBMA). The key...
The University of Rochester received a $423,500 Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research program) to investigate the role of mitochondrial dysfunction and oxidative stress in the progression of tau pathology in Alzheimer's disease. The two-year project will utilize novel optogenetic tools to spatiotemporally control mitochondrial function and reactive oxygen species production in both ex vivo brain slice cultures and an in vivo mouse model of tau...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $596,937 to the University of Wisconsin System to research the role of the RNA-binding protein FMRP in regulating mitochondrial function and energy metabolism in human neuron development. The 5-year project aims to: 1) investigate the impact of FMRP and its target RACK1 on...
The National Institute on Aging (NIA) awarded a $399,766 Project Grant (CFDA 93.866 - Aging Research) to the University of Kansas Center for Research Inc. to conduct research on understanding the dynamics between mitochondrial and nuclear genetic variation and their impact on mitochondrial dysfunction and associated diseases. The project will leverage threespine stickleback fish populations that exhibit high mitochondrial genomic diversity to study how nuclear genomes adapt to maintain...
This federal Project Grant award, funded by the National Institutes of Health (NIH) under the Research Infrastructure Programs (CFDA 93.351), aims to generate new animal models for studying mitochondrial DNA (mtDNA) diseases. The $629,508 grant, awarded to the University of Texas at Austin, will be used to accomplish three key objectives: Develop designer zebrafish models harboring specific mtDNA variants to study the differential roles of genetic variation in mitochondrial biology and...
This $177,310 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to investigate the molecular mechanisms underlying the protease YME1's role in mitochondrial protein quality control. The research aims to elucidate how YME1 selects and processes targeted protein substrates, with a focus on its unique ability to switch between processive...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will provide $622,000.00 to the University of Maryland, Baltimore to study the role of mitochondrial complex I deficiency in Alzheimer's disease and dementia. The key objectives are to: Determine the effects of complex I deficiency on humanized amyloid-beta (Aβ) proteinopathy, a hallmark of Alzheimer's disease. The researchers will develop a real-time quaking induced conversion (RT-QuIC) assay to...

MRNA LOCALIZATION AS A DRIVER OF MITOCHONDRIAL DYSFUNCTION DURING NEURODEGENERATION - PROJECT SUMMARY/ABSTRACT AGE-RELATED NEURODEGENERATIVE DISEASES ARE A CLASS OF INCURABLE DISEASES THAT RESULT IN THE PROGRESSIVE DEGENERATION OF NEURONAL CELLS. MITOCHONDRIA ARE ESSENTIAL CELLULAR ORGANELLES THAT ARE KEY SOURCES OF ATP GENERATED BY OXIDATIVE PHOSPHORYLATION. MITOCHONDRIA CONTAIN THEIR OWN DNA AND PROTEIN SYNTHESIS MACHINERY, YET 99% OF MITOCHONDRIAL PROTEINS ARE ENCODED BY NUCLEAR DNA AND MUST BE IMPORTED INTO THE MITOCHONDRIA. MITOCHONDRIA ARE DYNAMIC IN BOTH THEIR COMPOSITION AND STRUCTURE, FORMING DYNAMIC TUBULAR NETWORKS THROUGH FISSION AND FUSION REACTIONS. IN NEURODEGENERATIVE DISORDERS SUCH AS ALZHEIMER'S, PARKINSON'S AND HUNTINGTON'S DISEASE, THERE IS A PHENOMENON KNOWN AS MITOCHONDRIAL FRAGMENTATION, IN WHICH THE NORMAL, ELONGATED SHAPE OF MITOCHONDRIA BECOMES DISRUPTED AND THEY INSTEAD TAKE ON A MORE FRAGMENTED, ROUND APPEARANCE. HOW MITOCHONDRIAL FRAGMENTATION LEADS TO MITOCHONDRIAL DYSFUNCTION IS UNKNOWN, BUT IT IS IMPORTANT TO UNDERSTAND AS INHIBITION OF MITOCHONDRIAL FRAGMENTATION HAS BEEN FOUND TO BE PROTECTIVE IN DISEASE MODELS OF ALZHEIMER'S, PARKINSON'S AND HUNTINGTON'S DISEASE. WE PROPOSE A NOVEL HYPOTHESIS THAT STABLE LOCALIZATION OF NUCLEAR-ENCODED MITOCHONDRIAL MRNAS TO THE MITOCHONDRIAL SURFACE AND CO-TRANSLATIONAL TARGETING OF PROTEINS TO INDIVIDUAL MITOCHONDRIAL FRAGMENTS LEADS TO HETEROGENEITY IN THE EXPRESSION OF MITOCHONDRIAL PROTEINS ACROSS MITOCHONDRIAL FRAGMENTS DRIVING MITOCHONDRIAL DYSFUNCTION. THIS PROPOSAL SEEKS TO ESTABLISH BASIC PRINCIPLES OF THIS HYPOTHESIS. TO ACCOMPLISH THIS, WE WILL (AIM1) QUANTIFY THE HETEROGENEITY OF PROTEIN EXPRESSION ACROSS DIFFERENT MITOCHONDRIAL MORPHOLOGIES DRIVEN BY HUMAN DISEASE INDUCING PROTEINS AB42 AND HTT103Q. SECONDLY, WE WILL (AIM2) TEST THE IMPACT OF MRNA LOCALIZATION AND CO- TRANSLATION MITOCHONDRIAL PROTEIN INSERTION ON PROTEIN HETEROGENEITY AND MITOCHONDRIAL DYSFUNCTION. FINALLY, WE WILL (AIM3) ESTABLISH TOOLS FOR EXPLORING THIS QUESTION IN MAMMALIAN MODELS BY EXPLORING MITOCHONDRIAL MRNA LOCALIZATION AND PROTEIN HETEROGENEITY IN MAMMALIAN CELLS. IN THE SHORT TERM OUR GOAL IS TO ESTABLISH A NEW MODEL THAT EXPLAINS HOW MITOCHONDRIA BECOME DYSFUNCTIONAL ACROSS DIFFERENT MITOCHONDRIAL MORPHOLOGIES. IN THE LONG TERM WE WILL BUILD ON THESE DISCOVERIES BY CONDUCTING FURTHER INVESTIGATIONS USING MAMMALIAN MODELS OF NEURODEGENERATION.

Posted 4/9/24, 12:00 AM